We are live on ! Find out more
FOLD

Amicus Therapeutics

Delisted

FOLD was delisted on the 24th of April, 2026.

230 hedge funds and large institutions have $3.57B invested in Amicus Therapeutics in 2022 Q4 according to their latest regulatory filings, with 42 funds opening new positions, 91 increasing their positions, 64 reducing their positions, and 33 closing their positions.

New
Increased
Maintained
Reduced
Closed

42% more repeat investments, than reductions

Existing positions increased: 91 | Existing positions reduced: 64

27% more first-time investments, than exits

New positions opened: 42 | Existing positions closed: 33

22% more call options, than puts

Call options by funds: $8.86M | Put options by funds: $7.25M

17% more funds holding in top 10

Funds holding in top 10: 67 (+1)

11% more capital invested

Capital invested by funds: $3.2B → $3.57B (+$367M)

4% more funds holding

Funds holding: 222230 (+8)

5.45% less ownership

Funds ownership: 109.55%104.1% (-5.5%)

Holders
230
Holders Change
+8
Holders Change %
+3.6%
% of All Funds
3.7%
Holding in Top 10
7
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+16.67%
% of All Funds
0.11%
New
42
Increased
91
Reduced
64
Closed
33
Calls
$8.86M
Puts
$7.25M
Net Calls
+$1.61M
Net Calls Change
-$1.44M
Name Holding Trade Value Shares
Change
Change in
Stake
Balyasny Asset Management
26
Balyasny Asset Management
Illinois
$24.4M +$3.54M +314,888 +19%
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
27
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Ontario, Canada
$23.7M -$7.74M -687,800 -26%
Goldman Sachs
28
Goldman Sachs
New York
$23M -$1.49M -132,668 -7%
New York State Common Retirement Fund
29
New York State Common Retirement Fund
New York
$19M +$3.65M +324,248 +26%
T. Rowe Price Associates
30
T. Rowe Price Associates
Maryland
$18.2M +$354K +31,475 +2%
FC
31
Finepoint Capital
Massachusetts
$17.4M -$2.93M -259,925 -15%
PAM
32
Panagora Asset Management
Massachusetts
$15.2M +$364K +32,356 +3%
Bank of New York Mellon
33
Bank of New York Mellon
New York
$14.6M -$424K -37,691 -3%
Primecap Management
34
Primecap Management
California
$14.1M -$1.97M -174,800 -13%
RSCM
35
Rock Springs Capital Management
Maryland
$13M +$578K +51,300 +5%
Deutsche Bank
36
Deutsche Bank
Germany
$12.7M -$5.89M -523,256 -34%
N
37
Nuveen
North Carolina
$11.9M -$1.75M -155,443 -14%
Invesco
38
Invesco
Georgia
$10M +$1.07M +95,155 +13%
VOYA Investment Management
39
VOYA Investment Management
Georgia
$9.05M +$1.92M +170,357 +30%
RHJA
40
Rice Hall James & Associates
California
$8.64M -$73.4K -6,521 -0.9%
PCM
41
Peregrine Capital Management
Minnesota
$8.59M -$1.22M -108,494 -13%
CS
42
Candriam SCA
Luxembourg
$8.47M +$281K +25,000 +4%
Rafferty Asset Management
43
Rafferty Asset Management
New York
$8.42M +$934K +83,009 +14%
RCAMU
44
Rothschild & Co Asset Management US
Connecticut
$8.13M -$537K -47,732 -7%
Nordea Investment Management
45
Nordea Investment Management
Sweden
$7.77M -$48.4K -4,296 -0.7%
UBS Group
46
UBS Group
Switzerland
$7.04M +$4.42M +392,760 +214%
Wells Fargo
47
Wells Fargo
California
$6.65M +$1.21M +107,659 +25%
Two Sigma Advisers
48
Two Sigma Advisers
New York
$6.34M -$2.36M -209,500 -29%
O
49
OrbiMed
New York
$6.3M +$5.81M +516,000 New
Swiss National Bank
50
Swiss National Bank
Switzerland
$6.2M +$109K +9,700 +2%

FOLD Hedge Fund Activity: Q4 2022 in Review

230 of the 6,222 institutional investors tracked by Wall St. Rank reported a position in Amicus Therapeutics (FOLD) for Q4 2022, worth a combined $3.57B — up 11% from $3.2B a quarter earlier.

Buyers outnumbered sellers: 42 funds opened new FOLD positions and 33 closed out — a net gain of 9 holders — while 91 added to existing stakes and 64 trimmed.

The largest buyer was Pictet Asset Management (Switzerland), adding an estimated $55.7M. The largest seller was Janus Henderson Group, cutting an estimated $179M.

  • 230 institutional investors held Amicus Therapeutics (FOLD) as of Q4 2022, up from 222 in Q3 2022.
  • Funds reported $3.57B of Amicus Therapeutics stock for Q4 2022, up 11% quarter-over-quarter.
  • 42 funds opened new Amicus Therapeutics positions in Q4 2022 and 33 closed out, a net change of +9 holders.
  • The largest Amicus Therapeutics buyer in Q4 2022 was Pictet Asset Management (Switzerland), an estimated $55.7M added.
  • The largest Amicus Therapeutics seller in Q4 2022 was Janus Henderson Group, an estimated $179M sold.

Based on aggregated 13F filings for Q4 2022.